We submitted the expression sequences of all glioma patients from TCGA to the TIDE website for analysis and found that PDPN expression was higher in those samples predicted by TIDE to respond to immunotherapy than in samples that did not respond (Fig. 5E). The gene discussed is PDPN; the disease is central nervous system cancer.